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Editd by Jesus AvilaAbstract Heat shock protein-90 (Hsp90) buﬀers cells from
genetic mutations and environmental stresses. To test if this
capability reﬂects a normal physiological function of Hsp90 to
buﬀer cellular signals, the eﬀects of Hsp90 inhibition were
measured on activation of Akt. Inhibition of Hsp90 with
geldanamycin ampliﬁed Akt phosphorylation induced by insu-
lin-like growth factor-1 (IGF-1) or insulin, indicating that Hsp90
normally buﬀers these signals. Furthermore, with IGF-1 stimu-
lation Hsp90 inhibition increased p38 activation, produced
additive activation of p90RSK, and slightly increased the
duration of ERK1/2 activation. Hsp90 dampened Akt signaling
by facilitating phosphatase-mediated dephosphorylation of Akt.
Thus, Hsp90 not only buﬀers the cellular eﬀects of mutations and
stresses, but also buﬀers the magnitude and duration of
activation of proliferative and survival-promoting signaling
responses.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The chaperone protein, heat shock protein-90 (Hsp90), has
recently been recognized as a cellular buﬀer against deleterious
gene mutations and environmentally stressful conditions [1]. In
organisms as disparate as ﬂies and plants, functionally elimi-
nating the action of Hsp90 revealed hidden genetic mutations
that had been buﬀered by the chaperone, indicative of its
crucial role in balancing stability with the capability for change
[2–4]. This revelation followed the deﬁning role of heat shock
proteins in general as proteins capable of minimizing the im-
pact of toxic environmental insults, including their namesake
heat shock as well as many other potentially lethal conditions
[6–8]. The capacity of Hsp90 to buﬀer the impact of genetic
and environmental inﬂuences raised the question of whether
this is a specialized function mobilized under duress, or if it is
part of the normal physiological function of Hsp90 that was
initially recognized by the severe outcomes that occurred fol-
lowing unprotected exposure to mutations or insults [2,3]. In
other words, does Hsp90 buﬀer non-toxic cellular signals as
well as those that may be toxic?* Corresponding author. Fax: +1-205-934-3709.
E-mail address: jope@uab.edu (R.S. Jope).
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in non-toxic cellular signaling mechanisms, the present study
focused on signaling leading to activation of the protein kinase
Akt (also known as protein kinase B), a well-characterized
client protein of Hsp90. Stimulation of a variety of receptors
for growth factors, insulin, and other signaling molecules ac-
tivates a phosphatidylinositol 3-kinase (PI3K)-mediated sig-
naling pathway that leads to activation of Akt via dual
phosphorylation on serine-473 and threonine-308 on Akt
[9,10]. Many studies have shown that Akt is complexed with
Hsp90 [11–13]. Long-term (e.g., 24 h) inhibition of Hsp90 with
the Hsp90-selective inhibitor geldanamycin or its analogs
[14,15] causes degradation of Akt through the proteosomal
pathway [16–21]. However, previous investigations did not
examine the ramiﬁcations of inhibiting Hsp90 on the imme-
diate signals causing activation of Akt.
Therefore, this study tested if Hsp90 has a buﬀering capacity
in receptor-stimulated activation of Akt as well as other out-
comes of receptor activation. The results show that inhibition
of Hsp90 ampliﬁed activation of Akt following stimulation
with insulin-like growth factor-1 (IGF-1) or insulin. These
results suggest that Hsp90 buﬀers physiological as well as toxic
signaling activities.2. Materials and methods
2.1. Cell culture and treatments
Human neuroblastoma SH-SY5Y cells and human embryonic
kidney HEK293 cells were grown as described previously [22]. Cells
were grown in serum-free media for 24 h prior to treatment with
geldanamycin, 25 lM radicicol, 10 lM LY294002 (Alexis, San
Diego, CA), 50 ng/ml IGF-1 (Serologicals, Purchase, NY), 100 nM
insulin (Sigma, St. Louis, MO), or 25 lM 17-allylamino-17-de-
methoxygeldanamycin (17-AAG; generously provided by Dr. Rob-
ert J. Schultz, Developmental Therapeutics Program, National
Cancer Institute).2.2. Immunoprecipitation
To immunoprecipitate Akt, 3.5 lg of Akt1 antibody was incubated
with 25 ll of 50% protein G–Sepharose in binding buﬀer (100 mM
sodium phosphate, pH 7.2) for 2 h at 4 C followed by two washes with
binding buﬀer. The cell extract (100 lg protein) was precleared with 25
ll of 50% protein G–Sepharose for 2 h at 4 C. The extract was cen-
trifuged and the supernatant was incubated with the Akt1-conjugated
protein G–Sepharose for 18 h at 4 C. The immobilized immune
complex was washed three times with lysis buﬀer, mixed with 40 ll of
Laemmli sample buﬀer, placed in a boiling water bath for 5 min, and
the samples were immunoblotted for Hsp90 and Akt.ation of European Biochemical Societies.
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Cells were washed twice with phosphate-buﬀered saline and were
lysed with lysis buﬀer (20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM
EDTA, 2 mM EGTA, 0.5% NP-40, 1 mM sodium orthovanadate, 100
lM phenylmethanesulfonyl ﬂuoride, 0.1 lM okadaic acid, 50 mM
sodium ﬂuoride, and 10 lg/ml each of leupeptin, aprotinin, and pep-
statin). The lysates were sonicated and centrifuged at 20 800 g for 15
min. Protein concentrations were determined by the bicinchoninic acid
method (Pierce, Rockford, IL). Where indicated, for the preparation of
mitochondria and cytosolic fractions the harvested cells were homog-
enized by nitrogen cavitation (200 psi, for 5 min) in a cell disruption
bomb (Parr Instrument Co., Moline, IL) and fractions were prepared
as previously described [22]. Samples were mixed with Laemmli sample
buﬀer (2% SDS), placed in a boiling water bath for 5 min, proteins
were resolved in SDS–polyacrylamide gels, transferred to nitrocellu-
lose, and incubated with antibodies to phospho-Ser473-Akt, phospho-
Thr308-Akt, phospho-Ser9-GSK3b, phospho-Thr180/Tyr182-p38,
phospho-Ser380-PTEN (phosphatase and tensin homolog deleted on
chromosome 10), phospho-Thr202/Tyr204-ERK1/2 (extracellular sig-
nal-regulated kinases 1 and 2), phospho-Ser241-PDK1 (phosphoino-
sitide-dependent protein kinase 1), phospho-Ser380-p90RSK (Cell
Signaling, Beverly, MA), heat shock factor-1 (HSF-1; NeoMarkers,
Fremont, CA), total Akt (Sigma), total GSK3b (BD-PharMingen/
Transduction Laboratories, San Diego, CA), or Hsp90b (Stressgen,
Victoria, BC, Canada). Immunoblots were developed using horserad-
ish peroxidase-conjugated goat anti-mouse, or goat anti-rabbit IgG,
followed by detection with enhanced chemiluminescence, and the
protein bands were quantitated with a densitometer.Fig. 1. Inhibition of Hsp90 by geldanamycin promotes IGF-1-induced
Akt activation. (A) SH-SY5Y cells were treated with 1 lM geldana-
mycin for 0–160 min. Nuclear fractions were prepared and nuclear
levels of HSF-1 were measured by immunoblot analysis. (B) SH-SY5Y
cells were treated with 50 ng/ml IGF-1 for 0, 5, 10, or 20 min, with or
without pretreatment with 10 lM geldanamycin for 30 min. Levels of
phospho-Thr308-Akt, phospho-Ser473-Akt, and phospho-Ser9-
GSK3b were measured by immunoblot analysis. (C) Quantitative
values for phospho-Thr308-Akt were obtained from three independent
experiments and are meansS.E.M. P < 0:05. Ctl, control untreated
samples; GA, geldanamycin. (D) SH-SY5Y cells were treated with 10
lM geldanamycin for 24 h followed by measurements of total Akt,
phospho-Ser473-Akt, total GSK3b, and phospho-Ser9-GSK3b by
immunoblot analysis.3. Results
The transcription factor HSF-1 is a well-characterized
Hsp90 client protein. When complexed with active Hsp90,
HSF-1 is retained in the cytosol, but it translocates to the
nucleus when Hsp90 is inhibited or recruited to bind other
proteins [23,24]. Therefore, the nuclear level of HSF-1 can
provide a readout of inhibition of Hsp90, and this was used to
determine the rate of inhibition of Hsp90 after treating of SH-
SY5Y cells with geldanamycin. In untreated SH-SY5Y cells,
little HSF-1 was present in the nucleus, whereas treatment with
1 lM geldanamycin caused a rapid accumulation of HSF-1 in
the nucleus (Fig. 1A). There was a large increase evident within
10 min and maximal accumulation of nuclear HSF-1 was at-
tained after 20 to 40 min of geldanamycin treatment. This fast
accumulation of HSF-1 in the nucleus conﬁrms that the inhi-
bition of Hsp90 by geldanamycin is rapid.
To test if Hsp90 buﬀers the magnitude of Akt activation by
intracellular signaling, SH-SY5Y cells were stimulated with
IGF-1 (50 ng/ml) to activate the PI3K/Akt signaling pathway
with or without pretreatment with 10 lM geldanamycin. IGF-
1 treatment substantially increased Akt phosphorylation, as
indicated by large increases in the levels of both phospho-
Thr308-Akt and phospho-Ser473-Akt (Fig. 1B). The dual
phosphorylation of Akt occurred within 5 min of treatment
with IGF-1 and remained above control levels through 20 min
of incubation. The same treatment with IGF-1 after geldana-
mycin pretreatment resulted in much larger increases in the
dual phosphorylation of Akt. Quantitative analyses showed
that with geldanamycin treatment the rapid stimulation (5
min) of phospho-Thr308-Akt was nearly double the values in
cells stimulated with IGF-1 alone (Fig. 1C). Similar increases
caused by geldanamycin were evident 10 and 20 min after
stimulation with IGF-1. Treatment with IGF-1 also stimulated
an increase in the phosphorylation of the Akt substrate
GSK3b on serine-9, and this was greater in cells pretreatedwith geldanamycin (Fig. 1B), verifying that the phosphory-
lated Akt was active. These results indicate that inhibition of
Hsp90 allowed more Akt to be recruited and activated by the
IGF-1-stimulated signaling pathway.
Contrasting with geldanamycin’s facilitation of rapid sig-
naling to Akt, long-term treatment with geldanamycin (24 h)
to inhibit Hsp90 caused a large decrease in the level of Akt in
SH-SY5Y cells (Fig. 1D), as reported previously in SH-SY5Y
and other cell types [16,19]. With this treatment, there was also
no detectable phosphorylated Akt and there was a large de-
crease in the level of phospho-Ser9-GSK3b, indicative of in-
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aﬀected, indicating that the loss of Akt stems from its role as a
Hsp90 client protein. These responses demonstrate that Akt in
SH-SY5Y cells responds similarly to inhibition of Hsp90 fol-
lowing long-term treatment with geldanamycin as has been
observed in other cells.
To test if the promotion of Akt activation by geldanamycin-
induced inhibition of Hsp90 is a general response, we exam-
ined another cell type, HEK 293 cells, and used a diﬀerent
stimulant, insulin. Treatment with insulin (100 ng/ml) caused a
rapid and robust increase in the phosphorylation of Akt at
both Thr308 and Ser473 in HEK cells (Fig. 2). Quantitative
analysis of several experiments demonstrated that pretreat-
ment with geldanamycin increased the insulin-stimulated Akt
phosphorylation by approximately fourfold (Fig. 2). Thus, as
occurred with IGF-1 stimulation in SH-SY5Y cells, inhibition
of Hsp90 allowed greater activation of Akt by the insulin-
stimulated signaling pathway in HEK 293 cells.
The previous results revealed that geldanamycin treatment
promoted signaling to Akt induced by receptor-saturating
concentrations of IGF-1 or insulin. Lower concentrations ofFig. 2. Inhibition of Hsp90 by geldanamycin promotes insulin-induced
Akt activation. HEK 293 cells were treated with 100 nM insulin (INS)
for 0, 5, 10, or 20 min, with or without pretreatment with 10 lM
geldanamycin (GA) for 30 min. Levels of phospho-Thr308-Akt and
phospho-Ser473-Akt were measured by immunoblot analysis. Quan-
titative values for phospho-Thr308-Akt were obtained from three in-
dependent experiments and are means S.E.M. P < 0:05 compared
to matched samples not treated with geldanamycin.IGF-1 were used to compare geldanamycin’s ability to po-
tentiate activation of Akt at various signal strengths. Using 5,
10, 25, or 50 ng/ml IGF-1 to stimulate SH-SY5Y cells, it was
evident that even at the lowest concentration with the weakest
signal, geldanamycin greatly enhanced IGF-1-induced activa-
tion of Akt (Fig. 3A). In addition to geldanamycin, two other
inhibitors of Hsp90, 17-AAG and radicicol, also potentiated
IGF1-induced phosphorylation of Akt and the subsequent
increase in phospho-Ser9-GSK3b (Fig. 3B). Although gel-
danamycin inhibits Hsp90, it has been reported not to cause
the dissociation of Hsp90 from Akt (11). We tested if that also
held true with IGF-1 stimulation by measuring the amount of
Hsp90 that co-immunoprecipitated with Akt. Equal amounts
of Hsp90 co-immunoprecipitated with Akt following treat-
ment with geldanamycin, IGF-1, or both agents (Fig. 3C),
consistent with previous conclusions that Hsp90 and Akt re-
main in a complex regardless of the inhibitory eﬀect of gel-
danamycin.
Although Akt is predominantly a cytosolic enzyme, we re-
cently found that it translocates to the mitochondria following
stimulation [22]. Therefore, we tested if the potentiating eﬀect
of geldanamycin was selective for either of these pools of Akt.
In the cytosol, the dual phosphorylation of Akt was increased
in cells treated with both geldanamycin and IGF-1 (Fig. 3D).
Two eﬀects are evident in mitochondria: the translocation of
Akt into the mitochondria and the increase in Akt phos-
phorylation. The level of Akt in the mitochondria increased
following IGF-1 treatment and this mitochondrial import of
Akt was unaltered by geldanamycin pretreatment. However,
after geldanamycin treatment there were large increases in
both phosphorylation sites of Akt that accumulated in the
mitochondria. Thus, the IGF-1-stimulated phosphorylation of
both cytosolic and mitochondrial pools of Akt was increased
by geldanamycin pretreatment.
The activation of Akt is regulated by PDK1 and by PTEN.
Phosphorylation of threonine-308 of Akt is mediated by
PDK1, a kinase thought to be constitutively active that
phosphorylates Akt after Akt translocates to the 3-phosphoi-
nositides in the plasma membrane synthesized by the action of
PI3K [9]. We tested if geldanamycin treatment altered the
active state of PDK1, which can be detected by immunoblot
measurement of the active phospho-PDK-1. Treatment with
IGF-1 alone or with geldanamycin did not change the level of
phospho-PDK1 (Fig. 3E), indicating that the facilitation of
Akt phosphorylation by geldanamycin was not due to in-
creased activation of PDK1. Acting in opposition to PI3K,
PTEN mediates the hydrolysis of 3-phosphoinositides, thereby
reducing signaling to Akt, and is active when phosphorylated
on serine 380 (Fig. 3A). As with PDK1, neither treatment with
IGF-1 alone nor with geldanamycin plus IGF-1 altered the
level of phospho-PTEN, indicating that increased Akt activa-
tion after geldanamycin treatment was not due to inhibition of
PTEN. These results support the hypothesis that inhibition of
Hsp90 does not alter the magnitude of the signal directed to
Akt, but most likely reﬂects a direct interaction of Akt with
Hsp90.
The previous results indicate that active HSP90 limits sig-
naling-induced phosphorylation of Akt, since this response to
IGF-1 or to insulin was greater following inhibition of Hsp90
with geldanamycin. Therefore, we examined if inhibition of
HSP90 with geldanamycin inﬂuenced the activation of other
kinases after stimulation with IGF-1, including p38, ERK1/2,
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signature following stimulation with IGF-1 alone and in
combination with geldanamycin. There was virtually no acti-
vation of p38 following stimulation with IGF-1, but in the
presence of geldanamycin there was clearly strong phosphor-
ylation of p38 stimulated by IGF-1 (Fig. 3E). The phosphor-
ylation of p90RSK diﬀered from the other kinases in that both
IGF-1 and geldanamycin alone produced equivalent large in-
creases, and the two together caused an approximately addi-
tive eﬀect (Fig. 3E). ERK1/2 was rapidly phosphorylated
following IGF-1 treatment, which was maximal after 5 min
and then diminished after 10 and 20 min. Pretreatment withgeldanamycin did not alter the maximal phosphorylation of
ERK1/2 but slightly reduced the rate of dephosphorylation at
10 and 20 min after IGF-1 treatment (Fig. 3E). Thus, Hsp90
has widespread buﬀering eﬀects on the activities of signaling
pathways, and these vary in magnitude and duration. Thus,
inhibition of Hsp90 with geldanamycin does not cause a gen-
eral facilitation of IGF-1-induced signaling, but selectively
promotes speciﬁc downstream signals.
Inhibition of Hsp90 with geldanamycin could increase
stimulant-induced Akt phosphorylation either by blocking the
dephosphorylation of phosphorylated Akt or by enhancing the
phosphorylation process. To test if dephosphorylation was
aﬀected, we measured the dephosphorylation of phospho-
Thr308-Akt that followed inhibition of PI3K with LY294002.
Stimulation with IGF-1 activated Akt, this was potentiated by
geldanamycin pretreatment, and a subsequent incubation for
2.5 min with 10 lM LY294002 caused an approximately 80%
dephosphorylation of phospho-Thr308-Akt (Fig. 4A and B).
Pretreatment with geldanamycin increased the level of phos-
pho-Thr308-Akt stimulated by IGF-1, but subsequent treat-
ment with 10 lM LY294002 caused only a 33% decline. These
results indicate that inhibition of Hsp90 with geldanamycin
inhibits the phosphatase-mediated dephosphorylation of
phospho-Akt leading to increased levels in the presence of
geldanamycin.4. Discussion
The captivating concept of genetic buﬀering by Hsp90 [5]
has garnered widespread experimental and theoretical support
as a mechanism capable of ‘‘concealing the eﬀects of genetic
and environmental variation on phenotype’’ [25]. Such an in-
triguing concept naturally raises many questions. Among those
that we found especially interesting are the questions of pre-
cisely how such buﬀering is achieved and whether this mech-
anism is somehow reserved only for aberrant signaling
activities. By deﬁnition, buﬀering implies a dampening of the
magnitudes of ﬂuctuations. Therefore, we examined two hy-
potheses. First, that inhibition of Hsp90 would allow a greater
magnitude of signaling activity than in cells with active Hsp90.
Second, that the aﬀected signaling need not be aberrant, asFig. 3. Inhibition of HSP90 promotes IGF-1-induced intracellular
signaling. (A) SH-SY5Y cells were pretreated with 10 lM geldana-
mycin for 30 min followed by stimulation for 10 min with 0, 5, 10, 25,
or 50 ng/ml IGF-1. Phospho-Thr308-Akt and phospho-Ser473-Akt
were examined by immunoblot analysis. (B) SH-SY5Y cells were
pretreated with 25 lM 17-AAG or 25 lM radicicol (Ra) for 30 min
followed by stimulation for 10 min with 5 ng/ml IGF-1 and phospho-
Thr308-Akt and phospho-Ser9-GSK3b were measured. (C) SH-SY5Y
cells were pretreated with 10 lM geldanamycin (GA) for 30 min fol-
lowed by treatment with 50 ng/ml IGF-1 for 10 min. Akt was immu-
noprecipitated and the amount of Hsp90 that co-immunoprecipitated
was measured. The amount of Akt that was immunoprecipitated from
each sample is also shown. (D) SH-SY5Y cells were pretreated with 10
lM GA for 30 min followed by treatment with 50 ng/ml IGF-1 for 15
min. The cytosolic and mitochondrial fractions were prepared and
immunoblotted for phospho-Thr308-Akt, phospho-Ser473-Akt, and
total Akt. Ctl, control untreated samples. (E) SH-SY5Y cells were
treated with 50 ng/ml IGF-1 for 0, 5, 10, or 20 min, with or without
pretreatment with 10 lM geldanamycin for 30 min. Levels of phospho-
Ser241-PDK1, phospho-Ser380-PTEN, phospho-Thr180/Tyr183-p38,
phospho-Ser380-p90RSK, and phospho-Thr202/Tyr204-ERK1/2 were
measured by immunoblot analyses.
b
Fig. 4. Inhibition of Hsp90 blocks dephosphorylation of Akt. Cells
were treated with 10 lM geldanamycin (GA) 30 min prior to stimu-
lation with IGF-1 (50 ng/ml) for 10 min. Following IGF-1 treatment,
cells were treated with 10 lM LY294002 for 2.5 min. (A) Levels of
phospho-Thr308-Akt and phospho-Ser473-Akt were measured by
immunoblot analyses. (B) Quantitative values for phospho-Thr308-
Akt were obtained from three independent experiments and are
meansS.E.M. P < 0:05 compared to matched sample not treated
with LY294002.
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distinguish aberrant from normal signaling. To test these hy-
potheses, we focused on a signaling pathway that is well-
characterized as providing growth- and survival-promoting
cellular signals, that induced by IGF-1 or insulin leading to
activation of Akt. The results show that buﬀering by Hsp90
can indeed be achieved by dampening the magnitude of in-
tracellular signals and also demonstrate that this buﬀering
action is not limited to aberrant signals.
Perhaps, the most predominant post-translational modiﬁ-
cation that is used to modulate the activity of enzymes is
phosphorylation. In the case of Akt, dual phosphorylation on
Thr308 and Ser473 greatly increases the catalytic activity of
Akt, allowing it to eﬃciently phosphorylate many known
substrates [9,10]. This study of Akt showed that Hsp90 limits
the signaling activity of Akt by facilitating the removal of the
regulatory phosphates. This was evident because inhibition of
Hsp90 greatly diminished this dephosphorylation deactivating
process, allowing a signal (the dual phosphorylation of Akt) of
greater magnitude than that achieved in the presence of active
Hsp90. There is already solid evidence that protein phospha-
tases associate with Hsp90 and that Hsp90 can exert a regu-latory inﬂuence on their activities, since several reports have
demonstrated that Hsp90 binds to a number of protein phos-
phatases, such as protein phosphatase 2A [26], protein phos-
phatase 2B [27], and protein phosphatase 5 [28]. Thus, our
data indicate that Hsp90 facilitates phosphatase-mediated de-
phosphorylation of Akt, thereby buﬀering the magnitude of
the phosphorylation-dependent signaling activity that can be
achieved.
This regulatory interaction is very similar to the Hsp72-in-
duced suppression of c-Jun N-terminal kinase (JNK) phos-
phorylation and activation that has been described in detail by
Sherman and colleagues [29,30]. These investigators demon-
strated that Hsp72 promotes the activity of a JNK phospha-
tase to limit the phosphorylation of JNK. Dissociation of
Hsp72 from the phosphatase by damaged proteins inactivated
the phosphatase, allowing increased phosphorylation and ac-
tivation of JNK [31]. Similarly, our data indicate that Hsp90
promotes the activity of an Akt phosphatase and that inhibi-
tion of Hsp90 with geldanamycin impairs the ability of Hsp90
to promote the activity of the phosphatase, thereby allowing
enhanced phosphorylation of Akt. This buﬀering of Akt
phosphorylation could rely on an interaction between Hsp90
and a phosphatase or Hsp90 could aﬀect the conformation of
Akt to modulate its accessibility to phosphorylation or de-
phosphorylation.
Compared with the rapid responses of Akt-associated sig-
naling described here in which inhibition of Hsp90 is shown to
promote the phosphorylation of Akt, quite diﬀerent results are
obtained in studies of the longer-term eﬀects of inhibition of
Hsp90. The formation of a complex between Hsp90 and Akt
was ﬁrst reported by Sato and colleagues [11]. Subsequently,
most research on the Hsp90–Akt interaction has focused on
regulation of the stability of Akt, because inhibition of Hsp90
for several hours promoted the degradation of Akt [16].
Consequently, many reports have veriﬁed that Akt levels are
downregulated following six or more hours of inhibition
of Hsp90 [16–21]. However, the initial eﬀects of inhibition of
Hsp90 on intracellular signaling-induced phosphorylation of
Akt remained uninvestigated, and the current results demon-
strate that the initial outcome of inhibiting Hsp90 is facilita-
tion of the stimulant-induced phosphorylation of Akt. Thus,
although geldanamycin-bound Hsp90 causes destabilization of
Akt, this follows a more immediate facilitation of the phos-
phorylation of Akt.
In addition to Hsp90 dampening signaling associated with
phosphorylation of Akt, Hsp90 also was found to regulate
IGF-1-induced phosphorylation of several other intracellular
signaling kinases. These experiments revealed a variety of
regulatory actions of Hsp90 on the magnitude and/or duration
of signaling-induced phosphorylation of p38, p90RSK, and
ERK1/2. While the dampening of Akt signaling by active
Hsp90 was found to be due to the facilitation of dephospho-
rylation, the mechanisms underlying the modulation of p38,
pRSK90, and ERK1/2 by Hsp90 remain to be determined.
These multiple eﬀects of Hsp90 on diﬀerent kinases reveal the
individuality of its modulatory inﬂuences on diﬀerent intra-
cellular signaling proteins, actions that may contribute to the
capability of Hsp90 to buﬀer against genetic and environ-
mental stresses by limiting the magnitude of signaling ﬂuctu-
ations within the cells.
The capability of Hsp90 to regulate phosphorylation of Akt
reported here adds to a growing number of modulatory actions
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of which likely underlies its ability to buﬀer cellular events.
Hsp90 is currently known to associate with over 100 proteins
(reviewed in [32]). These proteins include kinases, receptors,
transcription factors, and a variety of others. Hsp90 has
multifaceted eﬀects on its variety of client proteins. These in-
clude assistance in the maturation or stabilization of clients,
such as the viral and cellular proto-oncogene Src [33,34],
maintenance of clients in inactive conformations, as with
glucocorticoid receptors [35], and other actions. Closest to the
action reported here, inhibition of Hsp90 with geldanamycin
was previously found to cause a rapid activation of the double-
stranded RNA-activated kinase PKR which coincided with
dissociation of Hsp90 from PKR [36], diﬀering with the stable
association of Hsp90 with Akt even after treatment with gel-
danamycin. Although Hsp90 limits phosphorylation of Akt, it
is interesting that Hsp90 can function as a molecular scaﬀold
to facilitate Akt-dependent phosphorylation of endothelial
nitric oxide synthase [12] and of telomerase reverse transcrip-
tase [37]. Thus, the interactions of Hsp90 and Akt are complex
and include attenuated phosphorylation of Akt but facilitated
stability and phosphorylation of Akt by certain targets. Thus,
Hsp90 has a diverse array of functions that often serve to
regulate the signaling activities of its clients, regulatory actions
that may underlie its capacity to buﬀer genetic and environ-
mental inﬂuences on cellular metabolism.
In summary, Hsp90 was shown to dampen signaling asso-
ciated with activation of Akt as well as several other intra-
cellular signaling kinases. These actions may contribute to the
capability of Hsp90 to buﬀer against genetic and environ-
mental stresses by limiting the magnitude of signaling ﬂuctu-
ations within cells.
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